David P. Meeker, President and CEO at RHYTHM PHARMACEUTICALS, INC. (RYTM), sold 50,000 shares at $101.75 ($5.1M) on 2026-09-14, disclosed to the SEC on 2026-09-14.
Scheduled sale ($5.1M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $101.75 | 6,439 | $655K | 12.8% |
| 2 | $102.35 | 30,746 | $3.1M | 61.3% |
| 3 | $103.43 | 8,698 | $900K | 17.5% |
| 4 | $104.55 | 1,817 | $190K | 3.7% |
| 5 | $105.19 | 2,300 | $242K | 4.7% |
| Total | $102.67 avg | 50,000 |
| $5.1M |
| 100% |
| Filing → |
| RYTM | SELL | 2025-02-04 | $508K | — | Filing → |
| TRVI | SELL | 2024-08-29 | $13K | — | Filing → |
| RYTM | SELL | 2024-03-19 | $3.6M | — | Filing → |